| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | BPD4DGQ314 |
Pharmacology
| Primary Target | |
|---|---|
| CD20 (membrane-spanning 4-domains, subfamily A, member 1) |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Arthritis, Rheumatoid | 2 | D001172 | ClinicalTrials |
| Purpura, Thrombocytopenic, Idiopathic | 1 | D016553 | ClinicalTrials |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | D054198 | ClinicalTrials |
| Lymphoma, Large B-Cell, Diffuse | 1 | D016403 | ClinicalTrials |
| Lymphoma | 1 | D008223 | ClinicalTrials |
| Lymphoma, Non-Hodgkin | 1 | D008228 | ClinicalTrials |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | D015451 | ClinicalTrials |
| Lymphoma, Follicular | 1 | D008224 | ClinicalTrials |
| Waldenstrom Macroglobulinemia | 1 | D008258 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 728917-18-8 |
| ChEMBL | CHEMBL1743088 |
| FDA SRS | BPD4DGQ314 |
| Guide to Pharmacology | 8268 |
CONTENTS